“Temporary Compounding” To Mitigate Off-Patent Monopolies
This article was originally published in RPM Report
FDA has two years of experience with self-registering compounding organizations. Is the agency ready to use them to address situations of access constraints from extreme pricing?
You may also be interested in...
Pharmacy benefit manager's anti-Daraprim effort signals new direction in pricing battles, but the strategy can only be used in limited circumstances.
US FDA asks oncology drug sponsors for information on the impact of modifications to clinical trials during the pandemic – with close attention to remote monitoring and data collection.
AstraZeneca devoted a surprisingly large piece of its testimony at the recent House vaccine hearing to its therapeutic work. The company appears to be anticipating another shift in public attention back to the mAB cocktail as a way to treat and prevent COVID-19.